Katsuyuki Hotta,
Katsuyuki Kiura,
Nagio Takigawa,
Hiroshige Yoshioka,
Hidetoshi Hayashi,
Hajime Fukuyama,
Akihiro Nishiyama,
Toshihide Yokoyama,
Shoichi Kuyama,
Shigeki Umemura,
Yuka Kato,
Naoyuki Nogami,
Yoshihiko Segawa, Masayuki Yasugi,
Masahiro Tabata,
Mitsune Tanimoto
[show abstract]
[hide abstract]
ABSTRACT: This study explores patient preferences for involvement in lung cancer treatment decisions and the extent of concordance between the views of patients and physicians on decisional roles. The impact of demographic and psychosocial characteristics on the decisional role of patients is also examined.
Patients with relapsed non-small cell lung cancer who were candidates for a phase II trial of erlotinib monotherapy were recruited. Patients were interviewed after they had learned of their relapse and the treatment decision had been made but before pharmacologic intervention.
Most of the 28 participants were married, had a smoking history, and were well educated. They reported moderate levels of depression and anxiety. Initially, 14% of the patients reported a preference for active decision making; later, 29% believed that the primary responsibility for the treatment decision had been theirs. Only 54% of the patients agreed with the physician's assessment of how the treatment decision was made (κ = 0.31; test of symmetry, p = 0.23). The depression score was significantly associated with a patient's preferred level of control (p < 0.01).
The limited concordance between patient preference and perception and between patient and physician perceptions regarding how the treatment decision was made suggests that physicians should more accurately identify patient preferences by directly asking patients at the beginning of each clinical encounter.
Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 10/2010; 5(10):1668-72. · 4.55 Impact Factor
